Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Multiple Sclerosis AND Fatigue

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: Multiple Sclerosis AND Fatigue. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2014-000254-11 Sponsor Protocol Number: 33375 Start Date*: 2014-03-28
    Sponsor Name:Department of Neurology
    Full Title: ROLE OF ENDOTHELIAL INFLAMMATION IN DEMYELINATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
    Medical condition: Mulple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001362-25 Sponsor Protocol Number: RAM-MS Start Date*: 2018-05-02
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis
    Medical condition: Relapsing remitting multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004980-36 Sponsor Protocol Number: MS200527-0082 Start Date*: 2020-09-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) LT (Completed) SK (Completed) LV (Completed) GR (Completed) BG (Completed) PL (Prematurely Ended) NO (Prematurely Ended) ES (Completed) DE (Prematurely Ended) SI (Completed) IT (Prematurely Ended) RO (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-003735-32 Sponsor Protocol Number: AB11005 Start Date*: 2015-04-01
    Sponsor Name:AB Science
    Full Title: A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients w...
    Medical condition: Prospective, multicentre, randomised, open-label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 mg/kg/day with switch to 4.5 then 6 mg/kg/day...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prohibited by CA) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004700-19 Sponsor Protocol Number: MS200527_0074 Start Date*: 2020-01-10
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsin...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004701-11 Sponsor Protocol Number: MS200527_0073 Start Date*: 2020-01-10
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsin...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000586-38 Sponsor Protocol Number: THIO-SM Start Date*: 2007-12-21
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS
    Medical condition: PATIENTS AFFECTED BY MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052785 HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002545-10 Sponsor Protocol Number: OSU6162Open1309 Start Date*: 2014-01-08
    Sponsor Name:A. Carlsson Research AB
    Full Title: An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g P...
    Medical condition: Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000541-12 Sponsor Protocol Number: AC-058B302 Start Date*: 2016-11-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who ...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Completed) DK (Completed) HU (Completed) CZ (Completed) AT (Completed) ES (Prematurely Ended) GR (Completed) BG (Completed) FR (Completed) PL (Completed) FI (Completed) BE (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004972-20 Sponsor Protocol Number: MS200527ˍ0080 Start Date*: 2020-11-05
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) HU (Prematurely Ended) BE (Completed) CZ (Completed) BG (Completed) ES (Completed) FI (Prematurely Ended) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000985-36 Sponsor Protocol Number: EMCAM-2011-001 Start Date*: 2013-02-22
    Sponsor Name:JOSE MANUEL GARCIA DOMINGUEZ
    Full Title: Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as "responders" and "not responders" under t...
    Medical condition: Spasticity due to multiple sclerosis identified as "responders" and "not responders" under treatment with Sativex
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10041416 Spasticity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005076-34 Sponsor Protocol Number: BEL-FMP-12-10325 Start Date*: 2013-01-03
    Sponsor Name:Cliniques Universitaires Saint-Luc, Neurologie
    Full Title: Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005989-37 Sponsor Protocol Number: 308841 Start Date*: 2006-03-29
    Sponsor Name:Schering Oy
    Full Title: CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis
    Medical condition: Observational Study to assess cognition in patients with early Multiple Sclerosis. Relapsing-Remitting MS-patients diagnosed within 2 years and who have started the Betaferon treatment (interferon-...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005211-21 Sponsor Protocol Number: 2005/00804 Start Date*: 2006-01-17
    Sponsor Name:Schering Oy
    Full Title: A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years
    Medical condition: Remitting relapsing multiple sclerosis (RRMS) is one of the most common diseases of the central nervous system. The cause of MS is not yet known but it is a result of damage to myelin. Symptoms var...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002373-95 Sponsor Protocol Number: 270682 Start Date*: 2021-01-07
    Sponsor Name:Haukeland University Hospital
    Full Title: Study of Mesenchymal Autologous stem cells as Regenerative Treatment for Multiple Sclerosis
    Medical condition: Multiple sclerosis (MS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000922-12 Sponsor Protocol Number: TV44400-CNS-40083 Start Date*: 2016-01-04
    Sponsor Name:Teva Pharmaceutical Industries, Ltd
    Full Title: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) IE (Completed) PL (Completed) FI (Completed) ES (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001205-23 Sponsor Protocol Number: OVERLORD-MS Start Date*: 2020-07-10
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS)
    Medical condition: Remitting Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000001-23 Sponsor Protocol Number: DroSpas-1 Start Date*: 2018-10-25
    Sponsor Name:Bionorica SE
    Full Title: A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in pat...
    Medical condition: Symptomatic relief of spasticity in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003498-41 Sponsor Protocol Number: D-Fampr Start Date*: 2015-09-22
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of dalfampridine on mobility in the context of daily life
    Medical condition: Motor behaviour and cognition in multiple sclerosis patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005493-11 Sponsor Protocol Number: CHPAU2014/01 Start Date*: 2015-08-31
    Sponsor Name:Centre Hospitalier de Pau
    Full Title: Intrathecal Rituximab in Progressive Multiple Sclerosis
    Medical condition: Patients included in our study suffer from a progressive form of Multiple sclerosis and will be treated by intravenous and intrathecal rituximab, with intravenous methylprednisolone.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 14:44:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA